Differentiating carcinoid syndrome from other diseases: Difference between revisions
No edit summary |
No edit summary |
||
Line 21: | Line 21: | ||
| colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
| | | | ||
! colspan=" | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 38: | Line 38: | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! | |||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
Line 56: | Line 57: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |somatostatin receptor scintigraphy [SRS], or Octreoscan | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |somatostatin receptor scintigraphy [SRS], or Octreoscan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metaiodobenzylguanidine (MIBG) scintigraphy | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metaiodobenzylguanidine (MIBG) scintigraphy | ||
! | |||
* Echocardiography | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid Syndrome | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid Syndrome | ||
Line 74: | Line 77: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Urinary 5-hydroxyindoleacetic acid (5-HIAA) | | style="background: #F5F5F5; padding: 5px;" |Urinary 5-hydroxyindoleacetic acid (5-HIAA) | ||
Line 95: | Line 99: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 116: | Line 121: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 121: | Line 127: | ||
|- | |- | ||
|Malignant neoplasms of small intestine | |Malignant neoplasms of small intestine | ||
| | |||
| | | | ||
| | | | ||
Line 142: | Line 149: | ||
|- | |- | ||
|Benign cutaneous flushing | |Benign cutaneous flushing | ||
| | |||
| | | | ||
| | | | ||
Line 163: | Line 171: | ||
|- | |- | ||
|Recurrent idiopathic anaphylaxis | |Recurrent idiopathic anaphylaxis | ||
| | |||
| | | | ||
| | | | ||
Line 200: | Line 209: | ||
!Imaging 2 | !Imaging 2 | ||
!Imaging 3 | !Imaging 3 | ||
! | |||
!Histopathology | !Histopathology | ||
|'''Gold standard''' | |'''Gold standard''' | ||
Line 221: | Line 231: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 242: | Line 253: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 263: | Line 275: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 21:31, 6 February 2019
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating carcinoid syndrome from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating carcinoid syndrome from other diseases |
FDA on Differentiating carcinoid syndrome from other diseases |
CDC on Differentiating carcinoid syndrome from other diseases |
Differentiating carcinoid syndrome from other diseases in the news |
Blogs on Differentiating carcinoid syndrome from other diseases |
Risk calculators and risk factors for Differentiating carcinoid syndrome from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome must be differentiated from systemic mastocytosis, medullary thyroid carcinoma, irritable bowel syndrome, malignant neoplasms of the small intestine, benign cutaneous flushing, and recurrent idiopathic anaphylaxis.
Differentiating Carcinoid Syndrome from other Diseases
Carcinoid syndrome must be differentiated from:[1]
- Systemic mastocytosis
- Medullary thyroid carcinoma
- Irritable bowel syndrome
- Malignant neoplasms of the small intestine
- Benign cutaneous flushing
- Recurrent idiopathic anaphylaxis
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||||
Abdominal pain | Diarrhea | Flushing | Dyspnea | Palpitations | Wheezing | Telangiectasia | Hypotension | Lab 1 | Serum Chromogranin A (CgA) | Lab 3 | Abdominal computed tomography (CT) | somatostatin receptor scintigraphy [SRS], or Octreoscan | Metaiodobenzylguanidine (MIBG) scintigraphy |
| ||||||
Carcinoid Syndrome | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | |||||||||||||||||||
Irritable Bowel Syndrome | ||||||||||||||||||||
Systemic mastocytosis | ||||||||||||||||||||
Malignant neoplasms of small intestine | ||||||||||||||||||||
Benign cutaneous flushing | ||||||||||||||||||||
Recurrent idiopathic anaphylaxis | ||||||||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Lab 1 | Lab 2 | Lab 3 | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings | |||||
Crohn disease | ||||||||||||||||||||
Asthma | ||||||||||||||||||||
Differential Diagnosis 6 |
References
- ↑ Metcalfe DD (2000). "Differential diagnosis of the patient with unexplained flushing/anaphylaxis". Allergy Asthma Proc. 21 (1): 21–4. PMID 10748948.